Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Citius Pharmaceuticals Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.79 (market cap $4.49B), while Citius Pharmaceuticals Inc trades at $0.56 (market cap $15.98M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 281× Citius Pharmaceuticals Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | CTXR | |
|---|---|---|
Market Cap | $4.49B | $15.98M |
Sector | Health | Health |
52-Week High | $28.06 | $1.94 |
52-Week Low | $20.06 | $0.53 |
Enterprise Value | $3.69B | $12.19M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
CTXR trades at $0.6075, up 5.73% in the last session, with a neutral technical signal and bearish moving averages. The company reported a net loss of $37.43 million for 2025, with a negative net income margin of -823.34%, while generating $5.6 million in revenue in the first half of 2026 from its LYMPHIR launch. Recent news highlights positive Phase 1 data for LYMPHIR presented at ASCO, though earnings have consistently missed expectations.
The outlook remains speculative, with significant upside potential if LYMPHIR gains commercial traction, but high execution risks and persistent losses pose substantial downside. Analyst consensus is strongly bullish at 83.3% buy ratings, reflecting optimism on the drug pipeline, yet investors face dilution risks from recent financing and the challenge of achieving profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
